Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07175506
PHASE1

Study of CM559 in Healthy Subjects

Sponsor: Keymed Biosciences Co.Ltd

View on ClinicalTrials.gov

Summary

This study is a single center, randomized, double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM559 administered intravenously at different doses in healthy male subjects.

Official title: A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM559 in Healthy Subjects With Single Ascending Dose Administration

Key Details

Gender

MALE

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-09

Completion Date

2026-06

Last Updated

2025-09-29

Healthy Volunteers

Yes

Interventions

DRUG

Placebo

Placebo injection administered IV, once.

BIOLOGICAL

CM559

CM559 injection administered IV, once.

Locations (1)

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China